Evidence map›Paper›PMID 29926527›Full record

ReviewCancer medicine2018

Vacuolar ATPase as a potential therapeutic target and mediator of treatment resistance in cancer.

Bradleigh Whitton, Haruko Okamoto, Graham Packham, Simon J Crabb

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04874935 (The Possible Efficacy and Safety of Lansoprazole Co-administration With Neoadjuvant Chemotherapy in Women With Breast Cancer), which is not on this map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04874935 phase3completednot on this mapstarted 2021, after this paper: background citation

The Possible Efficacy and Safety of Lansoprazole Co-administration With Neoadjuvant Chemotherapy in Women With Breast Cancer

TypeinterventionalSponsorTanta UniversityRan2021 to 2022Enrolled66ConditionsBreast CancerArmsLansoprazole, Placebo
3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 114 citations in OpenAlex.

  1. Article
  2. Review
  3. Vacuolar-type HNature communications · 2025
    Article
  4. Review
  5. Article
  6. Review
  7. Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  8. V-ATPase in glioma stem cells: a novel metabolic vulnerability.Journal of experimental & clinical cancer research : CR · 2025
    Article
  9. Acid affairs in anti-tumour immunity.Cancer cell international · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Bradleigh WhittonSouthampton Cancer Research UK Centre, University of Southampton, Southampton, UK.
Haruko OkamotoBiological Sciences, Faculty of Natural and Environmental Sciences, University of Southampton, Southampton, UK.
Graham PackhamSouthampton Cancer Research UK Centre, University of Southampton, Southampton, UK.
Simon J CrabbSouthampton Cancer Research UK Centre, University of Southampton, Southampton, UK.ORCID 0000-0003-3521-9064
Cancer Research UK · GBUniversity of Southampton · GB

Funding

Cancer Research UK
6 · The paper itself

Abstract

Vacuolar ATPase (V-ATPase) is an ATP-dependent H

Indexed as

Drug Resistance, NeoplasmAnimalsAntineoplastic AgentsBiomarkers, TumorGene Expression Regulation, NeoplasticHumansMolecular Targeted TherapyNeoplasmsProtein BindingStructure-Activity RelationshipVacuolar Proton-Translocating ATPasesAntineoplastic AgentsBiomarkers, TumorVacuolar Proton-Translocating ATPasescancerdrug resistanceinvasionmetastasisnovel therapyV-ATPase

Identifiers

PMID29926527
PMCPMC6089187
OpenAlexW2808804895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.